Good News for a Small-Cap Imaging Company
Executive SummarySchering AG's purchase of Diatide Inc. appears to be an exception to the general rule that, while small-cap acquisitions are at an all-time high, the shareholders of acquired companies don't fare particularly well. Schering areed to pay a significant premium over the the Diatide stock price just prior to the deal, despite the fact that Nycomed Amersham PLC owns partial rights to Diatides two late-stage products. Schering was willing to pay the price because of its commitment to developing a franchise in nuclear imaging.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.